Critical Comparison: Apollo Endosurgery (APEN) and Its Peers

Apollo Endosurgery (NASDAQ: APEN) is one of 106 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Apollo Endosurgery to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.

Profitability

This table compares Apollo Endosurgery and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apollo Endosurgery -41.50% -61.61% -26.55%
Apollo Endosurgery Competitors -73.49% -77.03% -18.12%

Analyst Ratings

This is a breakdown of recent ratings for Apollo Endosurgery and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollo Endosurgery 0 0 4 0 3.00
Apollo Endosurgery Competitors 534 1982 3874 134 2.55

Apollo Endosurgery presently has a consensus price target of $10.25, indicating a potential upside of 66.40%. As a group, “Surgical & medical instruments” companies have a potential upside of 3.82%. Given Apollo Endosurgery’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Apollo Endosurgery is more favorable than its peers.

Valuation & Earnings

This table compares Apollo Endosurgery and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Apollo Endosurgery $64.31 million -$27.29 million -3.06
Apollo Endosurgery Competitors $1.51 billion $110.21 million -198.29

Apollo Endosurgery’s peers have higher revenue and earnings than Apollo Endosurgery. Apollo Endosurgery is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Apollo Endosurgery has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Apollo Endosurgery’s peers have a beta of 0.77, indicating that their average share price is 23% less volatile than the S&P 500.

Institutional and Insider Ownership

31.8% of Apollo Endosurgery shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 52.8% of Apollo Endosurgery shares are owned by company insiders. Comparatively, 15.7% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Apollo Endosurgery beats its peers on 7 of the 13 factors compared.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply